Jellagen

Jellagen is a biotechnology and healthcare startup headquartered in the United Kingdom that has attracted significant attention with its revolutionary platform for regenerative medicine. Since its founding in 2013, the company has been dedicated to addressing complex regenerative medical needs and shaping next-generation treatments. At the core of their innovation is marine-sourced Collagen Type 0, an ancient stem collagen that enables a wide range of applications across multiple indications. This unique approach has garnered substantial interest, leading to a notable £8.70M Series A investment on December 7, 2022. The investment was secured from prominent backers including the Development Bank of Wales, Cardiff Capital Region, and the Thai Union Group. Jellagen's focus on leveraging jellyfish collagen for medical advancements has positioned it as a key player in the regenerative medicine space, making it a compelling prospect for investors seeking innovative opportunities in the healthcare sector.